DUBLIN, Dec. 20, 2018 /PRNewswire/ --
The "Global Prader-Willi Syndrome Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The number of pipeline molecules in the global PWS therapeutics market is increasing at a good phase. The pipeline has many promising therapeutics agents, which are expected to boost the market growth.
Approximately 15 therapeutics, are under different stages of development in the pipeline. The number of clinical trials is continuously increasing for the development of therapeutics for the treatment of PWS. This is expected to drive them market growth during our forecast period. These increasing number of special drug designations from regulatory bodies is expected to drive the market at a CAGR of close to 5% between 2018-2022.
Special drug designations
PWS is a rare disorder, and its prevalence rate is usually lower compared with other mainstream indications. Therefore, drug manufactures often hesitate to invest large amounts in drug discovery R&D. Therefore, regulatory bodies grant special drug designations, which will help in further development if the drug.
Lack of awareness of PWS
The sales of potential products are difficult to attain due to awareness issues. Though effective treatments available, individual attitudes, beliefs, poor treatment adherence and inadequate communication between clinicians and patients about PWS hinder the market growth.
This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the markets competitive landscape and offering information on the products offered by companies. The vendors in the market forming strategic alliances by acquiring businesses gain competitive advantages. The market is formatting alliances between public and private stakeholders. The companies constantly focusing improving their market positions, the competitive environment among the players is quite intense.
The latest trend gaining momentum in the market is the pipeline has many promising therapeutics agents, which are expected to boost the market growth. According to the report, one of the major drivers for this market is the increasing number of special drug designations from the regulatory bodies is expected to drive the market growth. Further, the report states that one of the major factors hindering the growth of this market is the stringent government regulations for marketing approval are excepted to hamper the growth of the market during the forecast period.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
PART 05: MARKET SIZING
- Market sizing 2017
- Market size and forecast2018-2022
PART 06: FIVE FORCES ANALYSIS
PART 07: PIPELINE LANDSCAPE
PART 08: MARKET SEGMENTATION BY PRODUCT
- Segmentation by product
- Comparison by product
- Recombinant growth hormones
- Market opportunity by product
PART 09: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 12: MARKET TRENDS
- Strong pipeline
- Increasing strategic alliances
- Use of advanced technologies for diagnosis and treatment of PWS
PART 13: VENDOR LANDSCAPE
PART 14: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Eli Lilly and Company
- Novo Nordisk
For more information about this report visit https://www.researchandmarkets.com/research/zgc7xs/global?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets